Clinical trial
A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT04204057 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Lead sponsor
- Rhizen Pharmaceuticals SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 28, 2019
- Completion date
- October 2, 2020
- Enrollment
- 21 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.